Loading
Metastasis and Carcinoma Case Studies / Mechanisms of Cancer Metastasis / Chromatin Remodeling and Cancer · Journal article
Frontiers in Immunology · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This single-center retrospective cohort of 22 patients with advanced SMARCA4-deficient NSCLC reports that ICI-containing chemoimmunotherapy achieved superior median OS (not reached vs 8.7 months, HR 0.28, 95% CI 0.08–0.98, p=0.047) compared to non-ICI therapy, with improved PFS, ORR and DCR. Addition of anti-angiogenic agents conferred no further survival benefit. Given the retrospective design, small size, and univariate analysis, these findings are hypothesis-generating rather than definitive, and the authors explicitly call for large prospective multicenter validation.
Single-center retrospective cohort study. Patients with immunohistochemically-confirmed advanced SMARCA4-deficient NSCLC treated at a single center. Most were elderly male smokers with high Ki-67, frequent adrenal metastasis, and low-to-negative PD-L1 expression.. Intervention: ICI-containing chemoimmunotherapy (with or without anti-angiogenic agents).. Compared with: Non-ICI-based therapy.. n = 22. Single center (not named in source)..
ICI-containing regimens versus non-ICI therapy: median OS not reached versus 8.7 months (HR = 0.28, 95% CI: 0.08–0.98, p = 0.047) ICI-containing regimens achieved improved progression-free survival, objective response rate, and disease control rate compared to non-ICI therapy Addition of anti-angiogenic agents to chemoimmunotherapy brought no extra survival benefit
Treatment-related adverse events were generally tolerable across groups
Clinicians managing advanced SMARCA4-deficient NSCLC may find a signal that ICI-containing chemoimmunotherapy offers survival advantage in this rare, previously unstandardized disease, even in immune-suppressed tumors. However, the small retrospective sample and univariate analysis mandate caution; these results should prompt prospective validation before informing individual treatment decisions.
Small single-center retrospective cohort (n=22) with univariate analysis only, addressing a rare disease with no established standard, yielding a promising survival signal but explicitly requiring large prospective validation.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians managing advanced SMARCA4-deficient NSCLC may find a signal that ICI-containing chemoimmunotherapy offers survival advantage in this rare, previously unstandardized disease, even in immune-suppressed tumors. However, the small retrospective sample and univariate analysis mandate caution; these results should prompt prospective validation before informing individual treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Introduction SMARCA4‑deficient non‑small‑cell lung cancer (SMARCA4‑dNSCLC) is a rare, aggressive NSCLC subtype driven by SWI/SNF complex dysfunction with no standardized therapeutic strategies. Although chemoimmunotherapy represents standard first‑line therapy for driver‑negative advanced NSCLC, its real‑world efficacy in SMARCA4‑dNSCLC remains controversial. SMARCA4 loss frequently generates an immune‑desert tumor microenvironment with low PD‑L1 and sparse CD8⁺ T‑cell infiltration, potentially conferring intrinsic resistance to immune checkpoint inhibitors (ICIs). Pre‑clinical data suggest synergism between anti‑angiogenic agents and chemoimmunotherapy; however, real‑world evidence comparing chemoimmunotherapy alone versus chemoimmunotherapy plus anti‑angiogenics for SMARCA4‑dNSCLC is limited. Methods This single‑center retrospective cohort enrolled 22 patients with immunohistochemically‑confirmed advanced SMARCA4‑dNSCLC treated from January 2021 to September 2024. Clinicopathological characteristics, treatment regimens, survival outcomes and safety data were collected. The Kaplan‑Meier method was applied to estimate progression‑free survival (PFS) and overall survival (OS). Given the small sample size, only univariate survival analysis was performed. Objective response rate (ORR) and disease control rate (DCR) were evaluated per RECIST 1.1, and treatment‑related adverse events were graded using CTCAE v4.0. This study obtained local ethics‑committee approval with informed consent waived. The last follow‑up date was September 1, 2025. Results Most patients were elderly male smokers with high Ki‑67, frequent adrenal metastasis and low‑to‑negative PD‑L1 expression. Compared with non‑ICI‑based therapy, ICI‑containing regimens achieved significantly superior survival: median OS not reached versus 8.7 months (HR = 0.28, 95%CI:0.08‑0.98, P = 0.047), accompanied by improved PFS, ORR and DCR. Addition of anti‑angiogenic agents brought no extra survival benefit. Elevated CYFRA21‑1 and poor ECOG‑PS predicted unfavorable prognosis. Treatment‑related adverse events were generally tolerable across groups. Conclusion Despite an immune‑suppressed tumor microenvironment, real‑world ICI‑containing chemoimmunotherapy delivers meaningful survival benefits for advanced SMARCA4‑dNSCLC, whereas additional anti‑angiogenic combination yields no further clinical advantage. Our findings should be interpreted cautiously given retrospective design and small sample size. Large‑scale multi‑center prospective studies incorporating multivariable prognostic analyses are required to validate these results and optimize individualized treatment for this rare molecular NSCLC subtype.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.